Lars Hanker
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, Breast Cancer Treatment Studies
Most-Cited Works
- → Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer(2023)738 cited
- → T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers(2009)480 cited
- → The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy(2012)336 cited
- → A clinically relevant gene signature in triple negative and basal-like breast cancer(2011)335 cited
- → Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer(2011)289 cited
- → Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group(2013)242 cited
- → Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial(2023)184 cited
- → Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial(2020)158 cited
- → Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)(2017)130 cited
- → Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study(2016)103 cited